Workflow
NuLeaf Naturals
icon
Search documents
High Tide Welcomes Historic Executive Order on Cannabis Rescheduling and Medicare Reimbursements for CBD Products
Prnewswire· 2025-12-18 19:52
The Company confirms it is assessing U.S. licensing pathways for its Canna Cabana retail brand NuLeaf Naturals and FAB CBD evaluating Medicare-aligned product categories CALGARY, AB, Dec. 18, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, today welcomed the Executive Order issued by the White House advancing the rescheduling of cannabis ...
Bull Of The Day: High Tide
ZACKS· 2025-08-26 12:11
Core Viewpoint - High Tide (HITI) is positioned as a strong investment opportunity in the cannabis sector, with positive growth projections and a favorable Zacks Rank of 2 (Buy) [1] Company Overview - High Tide, Inc. is a retail-focused cannabis company involved in the manufacture and distribution of consumption accessories, operating through Retail, Wholesale, and Corporate segments [2] - The company offers various brands including Canna Cabana, Fastendr, Grasscity, and others, and was founded in 2009, headquartered in Calgary, Canada [2] Earnings History - High Tide has experienced three consecutive misses of the Zacks Consensus Estimate, alongside one beat, with the most recent earnings showing a loss of -$0.03 against a consensus of -$0.02, resulting in a positive earnings surprise of 50% [4] Earnings Estimates Revisions - Earnings estimates for High Tide have been revised upward, with the full year 2025 loss estimate improving from -$0.05 to -$0.04, and 2026 estimates increasing from a gain of $0.06 to $0.11 [5] Growth Projections - Analysts project revenue of $421 million for the current fiscal year, indicating a 10.7% growth, with expectations of $548 million in the next fiscal year, representing a 29.9% sales growth [6] Valuation Metrics - High Tide does not have a forward PE ratio, but the projected multiple for the end of the next fiscal year is 31x, with a low price to book ratio of 2.9x and a price to sales ratio of 0.74x [7]